ESMO 2023 | Perioperative pembrolizumab for stomach cancer treatment

Kohei Shitara, MD, National Cancer Center Hospital East, Kashiwa, Japan, highlights the relevance of the KEYNOTE-585 (NCT03221426) study trialing perioperative pembrolizumab for locally advanced resectable gastric and gastroesophageal junction adenocarcinoma. Many patients require additional therapy following standard chemotherapy and surgery; as PD-1 inhibitors improved survival outcomes in patients with metastatic gastric cancer, pembrolizumab is being investigated in this setting, hopefully with beneficial results once again. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.